NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

1) it is a partial clinical hold;
2) the PR is not for a few years into it, Feb 2017. The news I believe broke from Adam in August of 2015 or so.

And as I said, we saw that the treatment arm was fully enrolled. It appears to me the meaning of that was intentionally unclear from the regulator so as not to spoil the trial, which is their duty, though their imposed crossover arm caused the depletion of the placebo arm to the point that it was not useful (fit for purpose). So the decision to stop enrolling that arm was a good one, but the challenge is in the nature of notions around clinical trials and their validity, which the regulators are working hard to address, to the consternation of traditionalists who have benefitted so far from the rigidity of things and their alignment with larger, well-funded companies and research programs.

I did not bring up the partial halt, and you did it again. I am just responding.